Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.346 EUR | +0.15% | +10.33% | -1.75% |
Apr. 10 | Transgene: presents vaccine results at AACR | CF |
Mar. 28 | Transgene CFO Steps Down; Successor Assumes Office | MT |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- The prospective high growth for the next fiscal years is among the main assets of the company
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- Low profitability weakens the company.
- The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
- The company's enterprise value to sales, at 3.81 times its current sales, is high.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-1.75% | 146M | C+ | ||
+2.97% | 108B | B+ | ||
+10.21% | 104B | B+ | ||
+1.57% | 22.33B | B | ||
-12.77% | 22.19B | B+ | ||
-7.05% | 18.69B | A- | ||
-37.64% | 17.74B | A- | ||
-6.50% | 17.64B | B | ||
+6.00% | 14.05B | C+ | ||
+37.20% | 12.51B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- TNG Stock
- Ratings Transgene